Paliperidone extended-release: Safety and tolerability from a metabolic profile perspective

Clinical Drug Investigation

Volumn 33, Issue 12, 2013, Pages 867-876

  Rodríguez Martínez, Alfonso ^a   Quilo, Carlos Guzmán ^b  

^a Centro Forum   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSOMNIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC PARAMETERS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; RECEPTOR AFFINITY; RECEPTOR BINDING; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOPHRENIA; SECONDARY ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; GLUCOSE; HUMANS; ISOXAZOLES; PYRIMIDINES; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84890303788     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0100-2     Document Type: Article

References (55)

1. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet. 1995;346(8973):477-81.
2. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Manag Care. 1998;4(3):369-83.
3. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269-92.
4. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
5. Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther. 1993;57(1):1-78.
6. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2):57-73.
7. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238-46.
8. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390-2.
9. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry. 2001;62(Suppl 7):4-10.
10. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf. 2001;24(1):59-73.
11. Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin. 2008;24(12):3341-55.
12. Fagan AL, Kissack JC, Augustin BG. Adverse events medication treatment costs in a chronically, severely mentally ill forensics population. Clin Schizophr Relat Psychoses. 2008;2(2):158-62.
13. Canuso CM, Youssef EA, Bossie CA, et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol. 2008;23(4):209-15.
14. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64(5):598-604.
15. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147-61.
16. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273-81.
17. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35.
18. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):856-65.
19. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1-17.
20. Hardy TA, Marquez E, Kryzhanovskaya L, et al. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol. 2006;26(4):405-8.
21. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425-33.
22. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl). 2005;183(3):383-6.
23. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007;27(4):374-9.
24. Khalili H, Dashti-Khavidaki S, Okhovatpour H, et al. Effects of risperidone on lipid profile. Ann Pharmacother. 2007;41(5):899-900.
25. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(Suppl 23):30-8.
26. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
27. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93.
28. Schooler NR, Gharabawi G, Bossie C, et al. A "virtual" comparison of paliperidone ER and oral risperidone in patients with schizophrenia [abstract]. 45th Annual Meeting of the American College of Neuropharmacology. 2006 Dec 3-7, Hollywood, p. S241-42.
29. Liberty IF, Todder D, Umansky R, et al. Atypical antipsychotics and diabetes mellitus: an association. Isr Med Assoc J. 2004;6(5):276-9.
30. Buckley PF. Update on the treatment and management of schizophrenia and bipolar disorder. CNS Spectr. 2008;13(2 Suppl 1):1-10 (quiz 1-2).
31. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-26.
32. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368-78.
33. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1-3):117-30.
34. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363-70.
35. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69(5):817-29.
36. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol. 2008;23(6):343-56.
37. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Invega™ (paliperidone) extended-release tablets: US prescribing information [online]. Available from http://invega.com/assets/prescribing-information.pdf. Accessed 24 May 2011.
38. European Medicines Agency. Invega™ (paliperidone): summary of product characteristics. 2006. http://www.ema.europa.eu/docs/en-GB/document- library/EPARProduct-Information/human/000746/WC500034925.pdf. Accessed 21 Oct 2013.
39. Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol. 2007;22(5):299-308.
40. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008;16(1):31-43.
41. Schreiner A, Tessier C, Hoeben D, et al. A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia. 15th Winter Workshop in Psychoses (WWP); 2009 Nov 15-18; Barcelona.
42. Jeppesen J, Hein HO, Suadicani P, et al. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med. 2001;161(3):361-6.
43. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6-14.
44. European Medicines Agency. Risperdal (risperidone): summary of product characteristics. 2011. http://www.medicines.org.uk/EMC/medicine/12818/SPC/ Risperdal+Tablets,+Liquid+%26+Quicklet/. Accessed 24 Oct 2013.
45. Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010;48(6):383-99.
46. Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3(6):869-97.
47. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(Suppl 18):27-35.
48. Citrome L. Paliperidone: quo vadis? Int J Clin Pract. 2007;61(4):653-62.
49. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769-79.
50. Degmecic D, Pozgain I, Filakovic P. Psychoeducation and compliance in the treatment of patients with schizophrenia. Coll Antropol. 2007;31(4):1111-5.
51. Janicak PG, Wu JH, Mao L. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials. Curr Med Res Opin. 2008;24(6):1807-15.
52. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23(10):2305-12.
53. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 1996;124(1-2):2-34.
54. Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol. 2012;32(4):449-57.
55. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18(2):63-101.